Alpha cognition to present zunveyl® (benzgalantamine) clinical data at 2025 alzheimer's association international conference

Vancouver, british columbia & dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (the “company” or “alpha cognition”) today announced three upcoming presentations at the 2025 alzheimer's association international conference (the “aaic”), taking place july 27–31, 2025 in toronto, canada. the presentations will highlight clinical studies supporting zunveyl (benzgalantamine), the company's lead product and a novel galantamine prodrug approved by the fda in july 2024 and commercially laun.
ACOG Ratings Summary
ACOG Quant Ranking